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Abstract
Antiangiogenic therapy is emerging as a highly promising strategy for the treatment of ovarian cancer, but
the clinical benefits are usually transitory. The purpose of this study was to identify and target alternative
angiogenic pathways that are upregulated in ovarian xenografts during treatmentwith bevacizumab. For this,
angiogenesis-focused gene expression arrays were used to measure gene expression levels in SKOV3 and
A2780 serous ovarian xenografts treatedwith bevacizumab or control. Reverse transcription-PCRwasused for
results validation. The insulin growth factor 1 (IGF-1) was found upregulated in tumor and stromal cells in the
two ovarian xenograft models treated with bevacizumab. Cixutumumab was used to block IGF-1 signaling in
vivo. Dual anti-VEGF and IGF blockade with bevacizumab and cixutumumab resulted in increased inhibition
of tumor growth. Immunohistochemistry measuredmultivessel density, Akt activation, and cell proliferation,
whereas terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) assay measured
apoptosis in ovarian cancer xenografts. Bevacizumab and cixutumumab combination increased tumor
cell apoptosis in vivo compared with therapy targeting either individual pathway. The combination blocked
angiogenesis and cell proliferation but not more significantly than each antibody alone. In summary, IGF-1
activation represents an importantmechanismof adaptive escape during anti-VEGF therapy in ovarian cancer.
This study provides the rationale for designing bevacizumab-based combination regimens to enhance
antitumor activity. Mol Cancer Ther; 11(7); 1576–86. 2012 AACR.
Introduction
Ovarian cancer arises from the epithelial layer cov-
ering the surface of ovaries and metastasizes intraper-
itoneally (i.p.). Tumor growth and metastasis rely
heavily on efficient development of new blood vessels
(1). The peritoneal environment is rich in secreted
factors, including VEGF (2), lysophophatidic acid (3),
platelet-derived growth factor (PDGF; ref. 4), TGF-b,
and others, which stimulate angiogenesis and growth
of ovarian tumors. Angiogenic signatures correlate
tightly with survival of patients with ovarian cancer
(5), underscoring the significance of angiogenesis to
ovarian tumor progression. Of these factors, VEGF
plays a significant role. Immunostaining detects VEGF
expression in most ovarian tumors and omental metas-
tases, and VEGF is measurable in ovarian cancer
patients’ ascites and serum (6). VEGF and VEGFR-2
expression levels in ovarian tumors are independent
poor prognostic factors (7–9) and correlate with surgi-
cal stage (10). VEGF is secreted in malignant ascites
at concentrations 50 to 200 times higher than in non-
malignant fluid (11) and serum VEGF concentrations
correlate with prognosis (12).
Antiangiogenic therapy (AAT) and particularly anti-
VEGF strategies have direct inhibitory effects on blood
vessels and may also block the proliferation of ovarian
cancer cells (13). Anti-VEGF agents inhibit angiogenesis,
destroy existent vessels, and facilitate normalization of
abnormally tortuous and fenestrated vessels (14, 15). The
effects on blood vessels lead to increasing hypoxia, nutri-
ent deprivation, and other dynamic changes in the tumor
microenvironment causing arrest of proliferation and/or
apoptosis of cancer cells (16).
Recent phase II studies have indicated that AAT is
highly effective in ovarian cancer (17–20). On the basis
of those results, bevacizumab, a humanized monoclonal
antibody to VEGF was investigated in the upfront treat-
ment of advanced stage ovarian cancer along with che-
motherapy (GOG protocol 218 and ICON 7; refs. 21, 22).
The recent results of these studies showed improvement
in progression-free survival for women treated with bev-
acizumab in combination with standard chemotherapy,
bringing the agent to the forefront of ovarian cancer
adjuvant therapy. However, although patients with ovar-
ian cancerderive initial clinical benefit frombevacizumab,
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this is usually transitory and has not translated into
improved long-term survival (21, 22).
It has been speculated that under the pressure of AAT,
adaptive escape and survival pathways emerge, facilitat-
ing alternative mechanisms of growth or metastasis. For
instance, in one study using glioblastoma and pancreatic
islet tumors, anti-VEGF therapy elicited activation of the
Met pathway leading to increased tumor invasiveness
(23–25). In another study using melanoma and sarcoma
models, treatment with anti-VEGF antibody increased
recruitment of myeloid cells (Gr1þ) to the necrotic areas
of tumors, altering the proinflammatory milieu (26, 27)
that led to increased propensity tometastasis.We hypoth-
esized that such adaptive mechanisms are activated in
ovarian tumors treated with bevacizumab and set out to
explore alterations of angiogenesis-related gene expres-
sion levels in ovarian cancer xenografts treated with
bevacizumab by using pathway-focused gene expression
arrays.
Here, we report that the insulin growth factor-1 (IGF-1)
is upregulated during treatment with bevacizumab of
ovarian xenografts and show that dual anti-VEGF and
IGFblockade results in enhanced tumor growth inhibition
comparedwith therapy targeting a single pathway. These
results point to IGF-1 upregulation as representing an
important mechanism of adaptive escape during anti-
VEGF therapy in ovarian cancer and provide the rationale
for designing bevacizumab-based combination regimens
to increase antitumor activity.
Materials and Methods
Ovarian cancer cell lines and materials
SKOV3 ovarian cancer cells were from the American
Type Culture Collection. A2780 cells were a gift from
Figure 1. Flow chart illustrates
design of experiments using
bevacizumab (Bev) in ovarian
xenografts and tumor response over
time. Two ovarian cancer cell lines
SKOV3 and A2780 were used. GE,
gene expression.
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Dr. J. Turchi of Indiana University (Indianapolis, IN) and
humanumbilical vein endothelial cell (HUVEC)cellswere
from Cell Applications. The cells were not authenticated.
SKOV3cellswere cultured ingrowthmedia containing1:1
MCDB 105 (Sigma) andM199 (CellGro), A2780 cells were
grown in Dulbecco’s Modified Eagle’s Medium (Sigma),
and HUVEC cells were cultured in endothelial growth
media supplemented with growth factors, as per provi-
der’s instructions (Cell Applications). Cancer cell media
was supplemented with 10% heat-inactivated FBS (Cell-
Gro) and 1% antibiotics (100 units/mL penicillin and 100
mg/mL streptomycin) and cells were grown at 37C in a
humidified 5% CO2 atmosphere. Cixutumumab was
provided by Dr. Ruslan Novosyadlyy of Imclone and
bevacizumab was purchased from Indiana University
Pharmacy. In vitro treatment with cixutumumab and bev-
acizumab used 20 and 75 mg/mL, respectively, for 3 days.
In vivo anti-VEGF and IGF therapy
Seven to 8-week-old female nudemice (nu/nuBALB/c)
were purchased from Harlan. Animal procedures were
approved by the Indiana University School of Medicine
Animal Care and Use Committee and were in accordance
with federal regulations. After acclimatization, A2780
cells or SKOV3 cells (5  106 cells/mouse) were injected
subcutaneously in the right flank. Tumorsweremeasured
weekly with calipers, and tumor volume in mm3 was
calculated according to the formula: volume ¼ width2
 length/2. Treatments were started when tumors
became measurable, usually within 1 week of s.c. tumor
implantation. To study tumor response to bevacizumab,
the agentwas administered i.p. at a dose of 5mg/kg twice
a week. Control mice were treated with 0.9% sodium
chloride. Treatmentwas continued until tumors exceeded
2 cm3 or animals showed signs of distress, at which point
mice were sacrificed and tumors were harvested, mea-
sured, and snap frozen.When possible, tumors from each
group were minced in the presence of hyaluronidase at a
concentration of 1 mg/mL and cultured. The xenograft-
derived cultures were characterized by proliferation
(MTT) and clonogenic assays.
To measure response to bevacizumab and cixutumu-
mab, mice were treated with bevacizumab (5 mg/kg, i.p.,
twice a week); cixutumumab (60 mg/kg, i.p., twice a
week); bevacizumab and cixutumumab (5 mg/kg, i.p.,
and 60 mg/kg i.p., respectively, twice a week), or v/v
saline control i.p. Each experimental group consisted of 5
to 6 animals. Both cell lines (SKOV3 and A2780) were
tested. Treatment continued for up to 3 weeks (A2780
cells) and6weeks (SKOV3 cells), atwhichpointmicewere
euthanized, tumors harvested and paraffin embedded for
future studies.
Angiogenesis PCR array
RNA was extracted from tumors harvested and snap
frozen from control and bevacizumab-treated animals
(n ¼ 3 per group and per cell line), by using the RNA
STAT-60 reagent (Tel-Test, Inc.). RNA was reverse-
transcribed using the RT2 First Strand Kit (C-03; SA
Biosciences), according to the manufacturer’s instruc-
tions. Genomic DNA contamination was eliminated by
DNAse treatment by using RNEasy Micro Kit (Qiagen
GmbH). Human Angiogenesis RT2 Profiler PCR Array
and RT2 Real-Timer SyBR Green/ROX PCR Mix were
purchased from SA Bioscience Corporation. PCR was
carried out on ABI Prism 7900 Sequence Detector
(Applied Biosystems). For data analysis, the DDCt meth-
od was used; for each gene, fold-changes being calcu-
lated as difference in gene expression between control
and bevacizumab-treated groups. A positive value indi-
cated gene upregulation and a negative value indicated
gene downregulation.
Reverse transcriptase PCR
RNA extracted from xenografts by using the RNA
STAT-60 reagent (Tel-Test, Inc.) was reverse-transcribed
Table 1. Genes induced by bevacizumab treatment in ovarian xenografts
Gene symbol Gene name Fold difference P
A2780
ID-1 Inhibitor of DNA binding 1 2.50 0.005
TNFAIP2 TNF-a–induced protein 2 6.64 0.039
IGF-1 Insulin growth factor 1 3.58 0.027
HPSE Heparanase 2.38 0.025
THBS-1 Thrombospondin 1 1.95 0.014
THBS-2 Thrombospondin 2 1.73 0.044
TIMP-1 TIMP metallopeptidase inhibitor 1 1.82 0.041
SKOV3
ANGPTL3 Angiopoietin-like 3 11.62 0.0243
COL4A3 Collagen, type IV, a 3 (Goodpasture antigen) 6.87 0.04
IGF-1 Insulin growth factor 1 7.07 0.045
IL-1b Interleukin-1b 5.24 0.044
S1PR-1 Sphingosine-1-phosphate receptor 1 1.95 0.045
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using the iScript cDNA synthesis kit (Bio-Rad). The PCR
reactions used Taq polymerase (Promega) and the follow-
ing primers: IGF-1 (forward): 50-CCTGCGCAATGGAA-
TAAAGT-30, (reverse): 50-TCAAATGTACTTCCTTCTG-
GGTC-30; GAPDH (forward): 50-GATTCCACCCA-
TGGCAAATTCC-30; (reverse): 50-CACGTTGGCAGTG-
GGGAC-30. For real-time PCR, we used the FastStart
TaqMan Probe Master (Rox, Roche) on an ABI Prism
7900 platform (Applied Biosystems) according to the
manufacturer’s procedures. The primers and probes
used are enclosed in Supplementary Table S1. At the
end of the PCR reaction, a melting curve was generated
and the cycle threshold (Ct) was recorded for the ref-
erence gene and for glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH). Relative expression of gene of
interest was calculated as DCt, measured by subtracting
the Ct of the reference gene from that of the control.
Results are presented as mean  SD of replicates. Each
measurement was carried out in duplicate and repeated
in independent conditions.
Western blotting
Tumors were minced on ice and resuspended in radio-
immunoprecipitation assay buffer containing protease
inhibitors leupeptin (1 mg/mL), aprotinin (1 mg/mL),
phenylmethylsulfonyl fluoride (PMSF; 400 mmol/L), and
sodium orthovanadate (Na3VO4; 1 mmol/L). Tumor or
cell lysates were sonicated briefly and subjected to cen-
trifugation at 14,000 rpm for 15minutes at 4C to sediment
particulate material. Equal amounts of protein (50 mg)
were separated by SDS–PAGE and electroblotted onto
polyvinylidene difluoride membranes (Millipore). After
blocking, membranes were probed with primary anti-
body overnight at 4C with gentle rocking. Antibodies
used are GAPDH (1:5,000 dilution; Biodesign Internation-
al), total IGF-1 receptor b, phospho-IGF-1 receptor b
(Tyr1150/1151), phospho-IRS-1 (Ser307), VEGFR-2 (Cell
Signaling), and Stat-5B (1:1,000; Santa Cruz; SC-1656).
After incubation with specific horseradish peroxidase–
conjugated secondary antibody, antigen–antibody com-
plexes were visualized using the enhanced chemilumi-
nescence detection system (Amersham Biosciences).
Images were captured by a luminescent image analyzer
with a CCD camera (LAS 3000, Fujifilm).
Immunohistochemistry
Immunohistochemistry evaluated multivessel density
(MVD) by staining for CD31, cell proliferation by staining
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Figure 2. IGF-1 expression upregulation in ovarian xenografts treated with bevacizumab. A, fold increase in gene expression levels induced by bevacizumab
treatment in ovarian xenografts, as measured by gene expression arrays. B, semiquantitative RT-PCR for human IGF-1 in control (n ¼ 3) and bevacizumab
(n ¼ 3)-treated A2780 xenografts (top) and densitometry analysis (bottom). C, qRT-PCR for human IGF-1 in control (n¼ 3) and bevacizumab (n¼ 3)-treated
A2780 xenografts (left). D, qRT-PCR for murine IGF-1 in control (n ¼ 3) and bevacizumab (n ¼ 3)-treated A2780 xenografts (right).
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for Ki67, and measured phospho-Ser473-Akt on paraffin-
embedded sections. Antibodies were from Cell Signaling
(phospho-Akt, 1:100 dilution), Dako (Ki67, clone M7248,
1:100 dilution), and from Abcam (CD31, 1:250 dilution).
After incubation with primary antibodies overnight at
4C, detection was obtained with the avidin-biotin per-
oxidase technique using theDAKODetectionKit (DAKO-
Cytomation). For phospho-Akt, scoring used a 0–3þ scale
for intensity and recording of the percentage of cells
staining. An H score was calculated as the product
between intensity and percentage of cells staining and
compared between groups. For Ki67, the numbers of
positive cells were counted per 5 high-power fields (HPF)
per specimen and average values were compared
between groups. MVD was assessed by counting the
number of vessels lined by CD31-positive endothelial
cells in 5 areas that appeared to have the highest vessel
density per specimen. Numbers of vessels were averaged
and compared between groups. Cell apoptosis was ana-
lyzedon frozen 5-mmthick tumor sectionswith In SituCell
Death (Apoptosis) Detection allowing terminal deoxynu-
cleotidyl transferase–mediated dUTP nick end labeling
(TUNEL) labeling (Roche Applied Science), according to
themanufacturer’s instructions.Numbers of cells staining
under UV excitation in 5 HPF per specimen were aver-
aged for comparison between groups.
Statistical analysis
Statistical analyses were conducted using SAS version
9.3. Shapiro–Wilk and Levene tests were used to test
normality and equal variance of the data, respectively.
When normality and equal variance assumptions held,
groups were compared using t tests or one-way
ANOVA with significant overall tests followed by pair-
wise tests adjusted for multiple comparisons using the
Student Newman–Keuls approach; otherwise Kruskal–
Wallis tests were done with significant overall tests
followed by pairwise exact Wilcoxon rank sum tests
adjusted for multiple comparisons using the Hochberg–
Bonferroni Step-Up approach. A P value of less than
0.05 was deemed significant. When an overall test was
not significant, post hoc tests (t tests or exact Wilcoxon
rank sum tests) were done to compare selected group
combinations.
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Figure 2. (Continued ) E, phosphorylation of IRS-1 in SKOV3 xenografts treated with vehicle (n¼ 3) or bevacizumab (n¼ 3) was detected by Western blotting
of homogenized tumor lysates (left). Densitometry analysis was conducted with Gel-Pro Analyzer 3.1 software (right). F, Western blotting for Stat-5b in
control (n ¼ 3) and bevacizumab (n ¼ 3)-treated SKOV3 xenografts SKOV3 xenografts (top). Densitometry analysis was conducted with Gel-Pro
Analyzer 3.1 software (bottom). G and H, qRT-PCR for human Stat-5b (G) and qRT-PCR for murine Stat-5b (H) in control (n ¼ 3) and bevacizumab
(n ¼ 3)-treated A2780 xenografts. For human genes (IGF-1, STAT-5b) qRT-PCR, human GAPDH was used as endogenous control. For murine genes
(IGF-1, STAT-5b), murine b-actin was used as endogenous control. Results are means  SE of 3 mice per group; , P < 0.05, signiﬁcantly different
from control.
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Results
IGF-1 is induced by treatment with bevacizumab in
ovarian xenografts
Quantitative pathway-focused gene expression analy-
sis was carried out in xenografts derived from 2 serous
ovarian cancer cell lines (SKOV3 and A2780) after treat-
ment with bevacizumab or control by using angiogenesis
gene expression superarrays (Fig. 1). These arrays permit
quantification of 92 angiogenesis-related genes and 6
housekeeping genes through quantitative RT-PCR meth-
odology. Xenografts derived from A2780 cells had a
doubling time of 4 days (control) versus 8 days (bevaci-
zumab); whereas xenografts derived from SKOV3 cells
had a doubling time of 7 days (control) versus 28 days
(bevacizumab). Six genes were significantly upregulated
in A2780 xenografts treated with bevacizumab compared
with control, at aP < 0.05 level of significance: ID-1, TNFa-
induced protein 2, IGF-1, heparinase, thrombospondin-1 and
2, and tissue inhibitor of metalloproteinase (TIMP)-1
(Table 1, Fig. 2A). Five genes were upregulated in SKOV3
xenografts treated with bevacizumab compared with
control: angiopoietin-like 3, collagen type 4a3, IGF-1,
interleukin-1b (IL-1b), and sphingosine 1 phosphate receptor
(P < 0.05, Table 1, Fig. 2A). Cells derived from SKOV3
xenografts treated with bevacizumab had increased pro-
liferation and clonogenic potential in vitro as compared
with ovarian cancer cells derived from xenografts treated
with vehicle (Supplementary Fig. S1A and S1B), suggest-
ing that exposure to bevacizumab engages escape
mechanisms that confer survival and proliferative
advantage.
As IGF-1 was the only gene upregulated by bevacizu-
mab in both xenograft models, and represents an impor-
tant survival factor under stress conditions (28), we
focused first on its validation and targeting. Semiquanti-
tative and quantitative RT-PCR showed increased IGF-1
mRNA expression levels in A2780-derived xenografts
treated with bevacizumab compared with control (Fig.
2B andC). Interestingly, both human (tumor-derived) and
mouse (host-derived) IGF-1 levels were increased in bev-
acizumab-treated xenografts compared with controls
(Fig. 2C and D) suggesting that both tumor and stromal
cells secrete IGF-1 in the environment exposed to beva-
cizumab. Furthermore, phosphorylation of the insulin
receptor substrate 1 (IRS-1), the adaptor protein that
conveys signals from the activated IGF receptor to down-
stream pathways, was increased in bevacizumab-treated
xenografts compared with controls (Fig. 2E). Collectively,
these data support that the IGF-1 pathway is activated
during anti-VEGF treatment of ovarian cancer xenografts.
It is known that IGF-1 is induced by cytokines and other
growth factors and is transcriptionally regulated by
STAT-5b (29, 30). We therefore measured protein and
mRNA levels of STAT-5b in tumors treated with bevaci-
zumab or control by Western blotting and by qRT-PCR.
STAT-5b protein expression level was increased in
SKOV3 xenografts during bevacizumab treatment (Fig.
2F), suggesting that this pathway is activated in vivo,
perhaps contributing to IGF-1 induction. Tumor (human)
STAT-5b was only modestly induced by bevacizumab
treatment, whereas stromal (host) STAT-5b expression
level was significantly increased in A2780 xenografts
treated with bevacizumab versus control (Fig. 2G and H).
Anti-IGF and -VEGF therapy has antitumor effect in
vivo
Based on the observation that IGF-1 is upregulated in
xenografts exposed to bevacizumab, we hypothesized
that combined therapy targeting the VEGF and IGF-1
pathways will exert potent antitumor effect. We tested
this by using cixutumumab (IMC-A12; ImClone Systems),
a fully human immunoglobulin G1 monoclonal antibody
that inhibits IGF signaling (31, 32) in combination with
bevacizumab. Cixutumumab prevents ligand binding to
IGF-1 receptor and promotes receptor internalization and
degradation. First, the effects of cixutumumab, bevacizu-
mab, and the combination of the 2 antibodies were tested
in vitro in endothelial (HUVEC) and tumor (SKOV3) cells.
Treatment with cixutumumab or with cixutumumab and
bevacizumab combination induced IGF-1 receptor
expression level downregulation in HUVEC and SKOV3
cells, consistentwith this antibody’s knownmechanismof
action (Fig. 3A and B). As anticipated, treatment with
bevacizumab did not affect IGF-1 receptor expression
level. Interestingly, in HUVEC cells, bevacizumab and
cixutumumab single agents also induced downregulation
of VEGF receptor 2, the main receptor involved in VEGF
signaling. The combination of cixutumumab and bevaci-
zumab significantly downregulated VEGFR2 expression
in HUVEC cells, as compared with each agent alone (Fig.
3A). These data suggest that cixutumumab has a direct
effect on VEGFR 2 expression levels and that this effect is
synergistic with bevacizumab’s effects.
Next, the activity of cixutumumab, of bevacizumab,
and of the combination of 2 antibodies was tested in vivo
in A2780 and SKOV3 xenografts. As a single agent, cix-
utumumab modestly inhibited the growth of A2780 and
SKOV3 subcutaneous xenografts whereas the combina-
tion of cixutumumab and bevacizumab exerted numeri-
cally superior effects as compared with each agent alone
in both tumor models (Fig. 3C and D, P < 0.05 for overall
tests).
Effects on tumor angiogenesis weremeasured by asses-
sing MVD in SKOV3- and A2780-derived xenografts.
Numerically, both single agents cixutumumab and bev-
acizumab decreased MVD in ovarian xenografts and the
combination regimen further reduced MVD compared
with each agent alone; however, the overall test was not
statistically significant (Fig. 4A and B, P ¼ 0.05 and
Supplementary Fig. S2A and S2B). Apoptosis was mea-
sured by TUNEL staining in xenografts treated with
control, cixutumumab, bevacizumab, and the 2 antibody
combination (Fig. 4C and D, P < 0.05 for the overall test).
Increased apoptosis was induced by the combination
bevacizumab and cixutumumab, but not by single agent
anti-VEGF or anti-IGF-1R antibody.
IGF and VEGF Blockade in Ovarian Cancer
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Treatment with bevacizumab and with cixutumumab
also inhibited cell proliferation, as assayed by Ki67 stain-
ing in SKOV3 and A2780 xenografts. The combination
cixutumumab and bevacizumab suppressedKi67, but not
to a greater extent than each agent alone (Fig. 5A and B,
and Supplementary Fig. S3C, P < 0.05 for overall test).
Decreased inAkt phosphorylation asmeasured by immu-
nohistochemistry was induced numerically by both cix-
utumumab and bevacizumab, but the results were not
statistically significant (Fig. 5C andD). Thesedata support
that cixutumumab and bevacizumab inhibit tumor
growth in vivo, by suppressing angiogenesis, cell prolif-
eration, and enhancing apoptosis.
Discussion
Blockade of tumor angiogenesis represents a promising
targeted therapy in ovarian cancer, however its effects are
transitory and impact on overall survival is not proven
(22). Identification of rational combinations to improve
the efficacy of antiangiogenic drugs is therefore impera-
tive and represents an unmet need. The goal of this study
was to gain a deeper understanding of the adaptive
response to anti-VEGF therapy in ovarian cancer models
and to identify pathways that are potentially responsible
for tumor escape under continued treatment with
bevacizumab.
Because one of the proposed resistance mechanisms to
anti-VEGF therapy is switch to and reliance on alternative
angiogenic pathways, we focused on discovering angio-
genesis-related genes altered in tumors exposed to bev-
acizumab. Interestingly gene expression array analysis
did not identify altered expression of the VEGF family
factors during bevacizumab treatment and this was con-
firmed by qRT-PCR for VEGF-A in ovarian xenografts.
However, IGF-1 upregulation was detected and was the
commondenominator in 2 independent xenograftmodels
tested versus the corresponding vehicle-treated controls.
Interestingly IGF-1, as measured by gene expression
arrays, was not significantly upregulated in SKOV3 xeno-
grafts after 4 weeks of bevacizumab treatment (e.g., at the
point of maximal tumor response, Fig. 1); but emerged as
an upregulated transcript in tumors resistant (A2780) or
persistent (SKOV3) during treatment with bevacizumab.
The interest in this candidate gene was further increased
by the availability of several agents targeting this path-
way, currently being evaluated in clinical trials (32) and
the significance of the pathway in ovarian cancer. IGF-1
stimulates growth of ovarian xenografts (33) and inhibi-
tion of the pathway with a neutralizing anti-IGF-1R anti-
body blocked tumor growth and reduced receptor sig-
naling through IRS-1, PKC, mitogen-activated protein
kinase (MAPK), and phosphoinositide 3-kinase (PI3K)-
AKT pathways (33, 34). IGF-1 expression in ovarian
tumors is associated with aggressive disease progression
and increased angiogenesis through both autocrine and
paracrine effects (35). Furthermore, IGF-1 receptor expres-
sion levels correlate with cisplatin resistance in ovarian
cancer cell lines (34). Collectively, these data support a
role of the IGF pathway in progression of ovarian cancer.
To our knowledge, our study links for the first time IGF-1
upregulation to escape during AAT.
For the experiments included in this report we used
cixutumumab, an antibody against IGF-1 receptor.
Cixutumumab downregulated the expression levels of
IGF-1 receptor in HUVEC and in SKOV3 cells and
downregulated VEGFR-2 in HUVEC cells, acting in a
synergistic manner with bevacizumab. The observed
synergistic effect of bevacizumab and cixutumumab
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Figure 3. Effects of bevacizumab, cixutumumab, and combination
bevacizumab and cixutumumab in vitro and in vivo. A, Western blotting
for IGF-1 receptor b, VEGFR-2, and phospho-IGF-1 receptor b in HUVEC
cells treatedwith cixutumumab (20mg/mL), bevacizumab (75mg/mL), and
the combinationof cixutumumabandbevacizumab.GAPDHwasusedas
control. B, Western blotting for IGF-1 receptor b, VEGFR-2, and p-IGF-1
receptor b in SKOV3 cells treated with cixutumumab (20 mg/mL),
bevacizumab (75 mg/mL), and the combination. GAPDH was used as
control. C, growth curve for SKOV3 xenografts. Results are means SE
of 6 mice per group; P < 0.05 for overall Kruskal–Wallis test at week 6;
cixutumumab was different from the combination therapy. D, growth
curve for A2780 xenografts. Results aremeansSE of 5mice per group,
P < 0.05 for overall ANOVA test at day 17. Control was different from all
other groups and cixutumumab alone was different from bevacizumab
and the combination therapy.
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in vivo supports the hypothesis that IGF-1 induction is
part of a key adaptive mechanism for tumor cells,
potentially under the selection pressure in the micro-
environment of bevacizumab-treated tumors. While our
original screen was aimed at the human cellular com-
ponent of the tumors, and revealed upregulation of
human IGF-1, our model affords the investigation of
the stromal contribution using species-specific primers.
Thus, we confirmed that stroma represents a major
source of IGF-1 in the resistant tumors. As cixutumu-
mab cross-reacts with the mouse IGF-1 binding to
receptors on the tumor cells, this component is also
neutralized by the antibody used, and may contribute
to the antitumor effect observed. However, at this point
we cannot reliably separate the specific contributions of
these 2 compartments to the tumor supporting IGF-1
pool.
The molecular mechanism of IGF-1 induction in our
models remains an open question. The complexity of
microenvironmental stress potentially relevant for tumor
adaptation to bevacizumab (increased hypoxia, nutrient
deprivation, more acidic pH) poses a considerable chal-
lenge for reconstructing this model in vitro. For example,
exposure of ovarian cancer cells in vitro to hypoxia or to
glucose deprivation failed to induce IGF-1 (not shown).
Exposure of ovarian cancer cells to both hypoxia and
glucose deprivation caused cell death in less than 6 hours.
However, the relevance of hypoxia to the mechanism
identified here cannot be ruled out simply based on this
simplified approach. We have documented hypoxia in
ovarian cancer xenografts exposed to bevacizumab by
measuring expression levels for 2 known hypoxia-induc-
ible target genes, carbonic anhydrase 9 (CA9), and micro-
RNA-210 (Supplementary Fig. S3). Furthermore, it is
documented that conditions in the tumor microenviron-
ment, such as hypoxia, can lead to enhanced responsive-
ness to IGF-1 (36),whichmight explain the reliance on this
specific pathway as an adaptive mechanism to antiangio-
genic treatment.
In addition, a mechanistic clue for IGF-1 induction may
be provided by STAT-5b, which we found to be robustly
upregulated in bevacizumab-treated tumors. STAT-5b is
both a hypoxia-inducible factor (37, 38) and a well-recog-
nized trigger for IGF-1 secretion (29, 39). STAT-5b is an
important regulator of cancer cell survival through mod-
ulation of antiapoptotic signals via Bcl-xL in prostate and
breast cancer and leukemia (40), 41, 42). STAT-5b along
with NF-kB complex’s Rel-A subunit have also been
Figure 4. MVD and apoptosis in
SKOV3 xenografts treated
with control, bevacizumab,
cixutumumab, and combination
bevacizumab and cixutumumab. A,
representative immunohisto-
chemical staining for CD31 shows
microvessel density in control,
cixutumumab, bevacizumab, and
combination-treated xenografts
(100 magniﬁcation). B,
quantiﬁcation of microvessel counts
was carried out in 5 HPF per
specimen in the4groups.Results are
means of counts in 5 HPF  SE of 3
specimens per group; results of
overall Kruskal–Wallis test were not
statistically signiﬁcant; the 2
bevacizumab groups combined
were different from control.
C, representative TUNEL
immunoﬂuorescent staining in
control-, cixutumumab-,
bevacizumab-, and combination-
treated xenografts. D, quantiﬁcation
of positive cells in the TUNEL assay.
Results aremeans of average counts
in 5 HPF per specimen  SE
(3 specimens/group). The overall
ANOVA test was signiﬁcant and
combination therapy was
signiﬁcantly different from both
single agents and the control.
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implicated in carboplatin resistance in ovarian cancer (43),
suggesting that this is an important survival pathway in
ovarian tumors. In that study, STAT-5b and Rel-A were
upregulated in recurrent postchemotherapy ovarian spe-
cimens compared with primary tumors, and the simulta-
neous knockdown of the 2 transcription factors sensitized
tumor cells to carboplatin (43). STAT-5b regulates other
angiogenic factors and members of the extracellular
matrix, such as VEGF-C and collagen type VI and XII
(42), and interestingly the JAK-STAT5 signaling axis also
regulates ID-1 expression (42, 44). We found ID-1 to be
upregulated in bevacizumab-treated xenografts and it is
possible that its regulation occurs downstream of STAT
signaling under these conditions. Interestingly, at least
based on our qRT-PCR data, STAT-5b induction appears
more robust in the stromal component of tumors com-
pared with tumor cells, consistent with higher induction
of murine IGF-1 in bevacizumab-treated tumors. These
observations argue for the importance of the tumormicro-
environment in the adaptive response to AAT.
A limitation of our study is the use of subcutaneous,
rather than intraperitoneal xenografts. Ovarian tumors
usually develop in the peritoneal space that has unique
characteristics favoring tumor development. The peri-
toneum consists of mesothelial cells that cover and
protect the viscera. The subperitoneal stroma contains
a collagen-based matrix, immune cells, activated fibro-
blasts, blood vessels, and lymphatics. Several studies
have shown an "activated" phenotype associated with
ovarian cancer, as opposed to its quiescent state in
benign conditions (45). The proinflammatory signature
associated with cancer consists of chemokines, cyto-
kines, and growth factors commonly upregulated in
the peritoneal milieu (45–47). While tumor cells play
a role in the secretion of factors that modulate angio-
genesis, more recently it has become accepted that
tumor infiltrating cells such as fibroblasts, myeloid cells,
immune cells, and endothelial precursors play a crucial
role modulating neovascularization (48). Future studies
will focus on intraperitoneal xenografts in an effort to
better mimic the development of ovarian tumors and
metastases in the peritoneal space.
We show that cixutumumab and bevacizumab syner-
gize in vivo blocking ovarian tumor growth and angio-
genesis. To our knowledge, these data provide the first
proof of principle that a combination between anti-VEGF
therapy and inactivation of the IGF pathwaymay provide
significant benefit over antiangiogenic drugs as single
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Figure 5. Immunohistochemistry
for Ki67 and phospho-Ser473-AKT
in control-, cixutumumab-,
bevacizumab-, and combination-
treated SKOV3 xenografts.
A, representative immunohisto-
chemical staining for Ki67 in
control-, cixutumumab-,
bevacizumab-, and combination-
treated xenografts (100
magniﬁcation). B, quantiﬁcation of
Ki67-positive cells was carried out
in 5 HPF per specimen in the 4
groups (n ¼ 3 specimens per
group). The overall ANOVA test
was signiﬁcant and all treatment
groups were different from control.
Representative C, immunohisto-
chemical staining for phospho-
Ser473-AKT in control-,
cixutumumab-, bevacizumab-,
and combination-treated
xenografts (100 magniﬁcation).
D, H scores were calculated as
described in Materials and
Methods. Results are means  SE
of 3 specimens per group; the
overall ANOVA test was not
statistically signiﬁcant. The 3
treatment groups combined were
different from control.
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agents and support further testing of this or of similar
combinations in patients with ovarian cancer.
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